YMZBY yields 2.10% · MRK yields 2.76%● Live data
📍 YMZBY pulled ahead of the other in Year 2
Combined, YMZBY + MRK cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of YMZBY + MRK for your $10,000?
Yamazaki Baking Co., Ltd., through its subsidiaries, manufactures and sells baked goods in Japan. Its products include loaf bread, sweet buns, donuts, hard rolls, and Danish pastries; Japanese, Western style, and rice-derived and based confectionery; processed bread and noodles, prepared rice, and side dishes; and chocolates, candies, stevia-based and other sweeteners, snack foods, and soup and soup stocks, as well as jams, marmalades, jelly and yokan products, and ready-to-eat curries in retort pouches. The company also manufactures biscuits, cookies, crackers, and frozen bread dough; provides coffee and juice under the Yamazaki brand; creams, curry fillings, stuffing for Chinese filled buns, croquettes, meat patties, and mayonnaise products; and prepared mixes for bread, tempura, and fried chicken, as well as sells products procured from other companies. In addition, it is involved in the manufacture and sale of cleaning and disinfecting agents for food production equipment; operation of bread and pastry shops, restaurants, convenience stores, and supermarkets; provision of retail bakery and cafe management, in-store bakery management, general truck transport and freight forwarding, and insurance services; and design of equipment for manufacturing bread and confectionery, installation of production facilities, and other services. Further, the company offers logistics management services; and manufactures and sells stevia-based and other sweeteners. As of December 31, 2021, it operated 1,389 stores. Yamazaki Baking Co., Ltd. was incorporated in 1948 and is headquartered in Tokyo, Japan.
Full YMZBY Calculator →Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Full MRK Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.